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Abstract—Cytotoxic platinum compounds play a major role in the chemotherapy of a large number 
of human cancers. However, due to the severe side effects for the patient and other problems associated 
with their use, there is a need for the development of more efficient drugs and new methods for their 
selective delivery to the tumours. One way to achieve the latter could be in the use of nanoparticular 
substrates that can adsorb or chemically bind the drug. In the cell, the drug is supposed to be slowly 
released, either by physical desorption or by dissolution of the particle framework. Ideally, the cytotoxic 
properties of the platinum drug unfold only then, in the cancer cell and over a longer period of time due 
to the gradual release. In this paper, we report on our first steps in this direction. The binding properties 
of a series of cytotoxic Pt(II) oxadiazoline compounds to mesoporous silica particles has been studied 
by NMR and UV/vis spectroscopy. High loadings were achieved when the Pt(II) compound was 
relatively polar, and has been dissolved in a relatively nonpolar solvent before the silica was added. 
Typically, 6-10 hours were required for complete equilibration, suggesting the adsorption did not only 
occur to the outer surface but also to the interior of the pores. The untreated and Pt(II) loaded particles 
were characterised by C, H, N combustion analysis, BET/BJH nitrogen sorption, electron microscopy 
(REM and TEM) and EDX. With the latter methods we were able to demonstrate the homogenous 
distribution of the Pt(II) compound on and in the silica particles, and no Pt(II) bulk precipitate had 
formed. The in vitro cytotoxicity in a human cancer cell line (HeLa) has been determined for one of the 
new platinum compounds adsorbed to mesoporous silica particles of different size, and compared with 
the corresponding compound in solution. The IC50 data are similar in all cases, suggesting that the 
release of the Pt(II) compound was relatively fast and possibly occurred before the particles reached the 
cells. Overall, the platinum drug is chemically stable on silica and retained its activity upon prolonged 
storage.  
 








Mesoporous silica nanoparticles have been studied in much detail and proposed as vehicles for the 
targeted delivery of drugs [1]. Among the promising properties of this material are the straightforward 
synthesis from easily accessible starting materials and the fact that both particle size and pore size can 
be tailored according to the reaction conditions applied. Additionally, the favorable adsorption 
characteristics for organic compounds allow for high loading and slow release in many cases, and the 
relatively high chemical inertness is important to avoid drug decomposition. Silica particles generally 
exhibit a high degree of biocompatibility, and their surface can be modified with biomarkers, to allow 
for targeting of cells with specific pathogenic characteristics. 
Pioneering studies targeted the drug delivery of the anti-psoriatic Alendronate bound to propylamine-
modified MCM-41 [2], the antibiotic Vancomycin adsorbed to CdS capped MCM-41 nanoparticles and 
its release through the action of reducing agents [3], or the photoresponsive release of the anti-cancer 
drug Paclitaxel from MCM-41 capped with Au nanoparticles [4]. In cancer chemotherapy, platinum 
complexes such as cisplatin, carboplatin and oxaliplatin play a major role, and targeted delivery to the 
cancer cells appears to be a promising approach to enhance drug efficiency and reduce toxicity 
connected with the adverse side effects experienced by the patient. Thus, it has been found that 
mesoporous silica microparticles delay and enhance the cytotoxicity of cisplatin and transplatin to 
leukemia cells [5], and delayed release of cisplatin from hybrid mesoporous silica particles has also 
been observed in another study [6]. The cisplatin delivery and anticancer effect was also examined 
using Pt(IV) cisplatin prodrugs attached to silica particles. In the reductive cellular environment, a Pt(II) 
species is formed and released [7]. Carboxyl-modified silica particles have been used to adsorb Pt drugs 
with high efficiency, leading to a higher loading [8], and this strategy has also been employed for the 
synthesis of mesoporous silica nanoparticle–oxaliplatin conjugates [9]. The adsorption kinetics of 
carboplatin to MCM-41 has been studied, but in this case the overall uptake seems to be fairly low [10]. 
In our previous work, we developed a type of cytotoxic platinum compounds bearing oxadiazoline 
ligands [11]. These compounds are of particular interest because of the absence of cross-resistance with 
cisplatin and carboplatin in in vitro experiments, offering a chance for complementary treatment of 
patients with an acquired resistance to the established drugs. Unfortunately, these compounds are 
relatively poorly soluble in aqueous media, making their administration difficult. There is also no active 
mechanism at work that would restrict uptake and activity to cancer cells. With the present work we 
attempt to address and overcome some of these problems.  
II. RESULTS AND DISCUSSION 
A. The Platinum Compounds 
The platinum compounds used in this work were synthesized and characterized as described 
previously [12]–[14]. Their structures are shown in Fig. 1, together with an outline of the synthesis. All 
compounds have a trans-configured PtCl2(oxa-diazoline) moiety in common, but the residual ligand 
varies from benzonitrile (in 2) to oxadiazoline (in 3), pyridine (in 4) and 7-nitro-1,3,5-triazaadamantane 
(in 5 and 6).  
B. The Mesoporous Silica Particles 
MCM-41-type mesoporous silica nanoparticles have been synthesized as described in the literature 
[15], starting from CTAB and TEOS in aqueous methanol solution. The ratio MeOH:H2O determines 
the particle size, whereas the pore size is defined by the nature of the surfactant used in the formation 
of the template micelles. The general synthetic strategy is shown in Fig. 2. Three samples, A, B and C, 
have been made, using MeOH:H2O ratios of 0.81, 0.67 and 0.54, under otherwise identical conditions. 
The samples were characterized by TEM, BET/BJH and C,H,N elemental analysis, and the results are 






Fig. 3 shows the result of a typical TEM experiment. The spherical particles are well dispersed but 
show a considerable size distribution. The program ImageJ [16] was used to determine the average size 
and the standard deviation over a representative number of particles, typically 50 to 200. The smaller 
particles thereby showed larger standard deviations and also had a slight tendency to agglomerate. 
 
Fig. 1 Synthesis of the platinum compounds used in this work [12]–[14]. R = 2-methoxyphenyl; L = 
7-nitro-1,3,5-tri-azaadamantane 
 









CHARACTERISATION OF THE SILICA PARTICLES A, B AND C 
Quantity [unit] Method A B C 
Average size [nm] TEM 229 120 36 
Stand. deviation [nm] TEM 23,3 42.8 25.2 
Surface area [m2 g-1] BET 603.53 746.47 802.98 
Pore diameter [nm] BJH (adsorption) 2.618 2.627 2.095 
Pore volume [cm3 g-1] BJH (adsorption) 0.652 0.731 0.974 
% C microanalysis 0.04 0.06 0.16 
% H microanalysis 0.03 0.04 0.07 
% N microanalysis 0 0 0 
 
 
Fig. 3 TEM of the mesoporous silica particles A (top), with scale bar = 0.2 μm. Size distribution 
measured over a total of 202 particles (bottom); average size = 229 nm, standard deviation = 23.3 nm 
 
BET/BJH provide consistent data about the surface area and pore diameter and volume. All values 
are in a range one would expect for MCM-41 type particles, due to the use of the same surfactant 
(CTAB), the pore diameter is constant, apart from sample C, where the pores seem to be a bit smaller. 
From the C,H,N microanalysis it can be concluded that the surfactant has been completely removed 
from the pores of the particles A and B. C seems to contain a small amount of residual CTAB, although 
the same extraction procedure was employed. This could account for the slightly smaller pore size 
observed for this sample. 
C. Loading of the Particles with the Pt Compounds 
1H NMR was used to follow the uptake of the Pt compounds by the silica particles. At first, the 
adsorption kinetics were addressed. Compound 5 (3.05 mg, 4.5 mmol) was dissolved in 0.6 ml of CDCl3 
and a 1H spectrum was taken. The intensity ratio between the residual CHCl3 signal of the solvent and 
the aromatic signal of 5 at 8.95 ppm was used as a reference = 100%. Then, 50 mg of A was added to 
the sample and 1H spectra were measured in regular time intervals over a period of 24 hours. Between 
the experiments, the sample was shaken and then left for sedimentation of the particles. Over time, the 
relative signal intensity, showing the amount of dissolved compound, decreases exponentially to 
disappear below the detection limit after about 6 h. Compounds 2, 3, 4 and 6 show fairly similar 






other signals than those of the platinum compound, suggesting sufficient stability in the presence of the 
silica particles.  
Next, we studied the loading capacity of the silica materials with respect to the individual Pt 
compounds, using a similar technique. Again, 3.05 mg of 5 was dissolved in 0.6 ml of CDCl3 and a 1H 
spectrum was taken to obtain the relative signal intensity for 100% dissolved compound. The silica 
material A was added in 5 mg portions. After each addition, the sample was left at room temperature 
for 24 h, and then a 1H NMR was recorded. This was repeated until the signals of 5 could be no longer 
detected. The results for 5 and the other Pt compounds is shown in Fig. 4. Thus, 3.05 mg of 5 can be 
adsorbed onto 30 mg of A, suggesting a loading of approx. 10 weight %. The other compounds are less 
polar than 5, and the loading, expectedly, is a little lower, in a range of 8-9 weight %. 
 
Fig. 4 Loading capacity of silica particles A for the platinum compounds 2 – 6, as determined by             
1H NMR spectroscopy. 
 
To determine the concentration of the platinum compounds left in solution, the particles were 
removed by centrifugation and the supernatant solution examined by UV/vis spectroscopy at 278 nm. 
Typical concentrations in a range of 2 x 10-5 (for 5) to 4 x 10-5 mol/l (for 3) were found, corresponding 
to 0.4 to 0.9 % of the initially applied amount of the Pt compounds.  
D. Characterisation of the Platinum-Loaded Particles 
The Pt loaded particles thus prepared were isolated by centrifugation and dried at 45 oC in a vacuum 
of 12 mm (membrane pump) for 6 h. The results from C, H, N analysis, shown in Table II, is consistent 
with an approximate 10 weight % loading for compound 5, and slightly lower loadings in a range of 9 
weight % for the other compounds. 
The weight % loadings were determined from the C and N microanalysis data only and averaged over 
these two elements. H was not used because it was always found too high relative to C and N, and this 
can be attributed to residual moisture adsorbed to the particles. At higher drying temperatures, however, 
the Pt compounds noticeably decomposed and a colour chance from pale yellow to brownish could be 
observed. Also the C, H, N analysis taken afterwards gave results inconsistent with the Pt compound 
used. 
TEM experiments confirmed that the particle size and distribution has not changed during adsorption 
of the platinum compounds, although a slightly higher tendency towards agglomeration could be 










C, H, N MICROANALYSIS DATA OF THE SILICA PARTICLES A, B AND C, LOADED WITH PLATINUM 
COMPOUNDS 3 AND 5 
Quantity [unit] A2 B2 C2 A3 B3 C3 
% C 4.28 4.19 4.36 4.56 4.62 4.67 
% H 0.36 0.47 0.57 0.35 0.48 0.59 
% N 0.58 0.60 0.51 0.62 0.66 0.59 
Loading [weight%] 9.3 9.6 8.9 9.2 9.5 9.1 
 A4 B4 C4 A5 B5 C5 
% C 4.02 4.10 4.18 3.92 3.88 3.75 
% H 0.38 0.40 0.56 0.47 0.52 0.51 
% N 0.61 0.65 0.63 1.25 1.21 1.18 
Loading [weight%] 9.4 9.7 9.6 10.4 10.2 9.8 
 A6 B6 C6    
% C 3.62 3.59 3.71    
% H 0.31 0.34 0.53    
% N 0.89 0.80 0.82    
Loading [weight%] 9.8 9.3 9.5    
The Loading was calculated from the C and N analytical data and averaged. 
 
   
(a)                                                    (b) 
    
(c)                                                    (d) 
Fig. 5 Elemental distribution measured by EDX mapping. (a) TEM image of one representative 
particle of A5; (b) TEM image overlayed with Si-L and Pt-M EDX scans; (c) Pt-M EDX scan; (c) Si-
L EDX scan 
 
The elemental distribution, in particular the distribution of Pt across the silica particles was 
determined from EDX scans, using the Si-K and Pt-M line. As can be seen in Fig. 5 for a representative 
particle of A5, there is a clear co-localization of platinum and silicon, and the homogenous distribution 







E. In vitro Cytotoxicity 
The in vitro cytotoxicity of A5, B5 and free 5 in solution in the epithelial human cancer cell line HeLa 
[17] was determined by means of the CellTiter-Glo® luminescent cell viability assay [18], as described 
in the experimental part. HeLa cervical cancer cells are known to respond to cisplatin with an IC50 of 
1.1 to 1.3 μM [19], and compound 5, with an IC50 of about 4.8 μM, is only slightly less potent. For 
carboplatin, an IC50 of 10.0 μM is reported [20]. 
The Pt loaded silica materials A5 and B5 were applied to HeLa cells as aqueous sonicated suspension, 
at Pt levels equal to those used before for free 5. For comparison, pure A and B were also testet, to 
demonstrate the biocompatibility of the material in a concentration range used in the other experiments. 
Overall, the cell viability profile of A5 and B5 strongly resemble that of the free drug and also the IC50 
data are practically the same. This suggests that the release of the Pt(II) compound was relatively fast 
and possibly occurred before the particles reached the cells. Overall, however, the platinum drug is 
chemically stable on silica and retained its activity even upon prolonged storage of several months. 
 
Fig. 6 Cell viability after 24 h of incubation in the presence of the free Pt compound 5 and the silica-
bound analogues A5 and B5, as well as the Pt-free silica nanoparticles A-blank and B-blank. Data are 
mean values over three experiments and given relative to untreated cells = 100 %. The dashed line 




In summary, we showed in this work that a series of novel platinum compounds, which had been 
identified as promising candidates for cancer treatment before, can be adsorbed to mesoporous silica 
nanoparticles as drug delivery systems. Depending on the polarity of the compounds, loadings of 9 – 
10 weight % can be achieved, which is in a practicable range for drug delivery systems, in particular 
when the drug is highly active. The distribution over the particles is fairly homogenous, as shown by 
EDX experiments, suggesting that binding takes place by molecular adsorption (rather than co-
crystallisation). The resulting materials exhibit a good shelf live and general stability, and the handling 
and dosage of aqueous suspensions is far easier than the use of solutions of the poorly water soluble 
free platinum compounds. In vitro experiments with one of the platinum compounds (5) demonstrated 
a cytotoxicity similar to cisplatin in HeLa cervical cancer cells, and the activity is fully retained when 
the silica bound materials A5 and B5 were used. However, the drug release seems to occur pretty fast 
and most likely before the particles enter the cells.  
Controllable drug release has not been achieved yet but this will be addressed in our future work. 






enzymatically hydrolysable functional group, so that cleavage from the silica particle only takes place 
after the particle has entered the cell. Another option is the secondary modification of the Pt-loaded 
silica particles, where a bio-degradable material is used to block the pore exits of the Pt loaded particles 
and prevent premature loss of the active drug. Once drug release can be actively controlled, 
improvements with respect to the delivery will be aimed for. So far, only some degree of passive 
targeting can be expected to occur as a result of the leaky vasculature and impaired lymphatic function 
of tumor tissues. More efficient active targeted delivery to cancer cells should be feasible by modifying 
the particles with a relevant biomarker. Work in this direction is in progress. 
IV. EXPERIMENTAL PART 
Instrumentation: 1H NMR spectra were recorded on a Bruker 400 MHz spectrometer in CDCl3 
solution. C,H,N elemental analysis data were obtained from a Elementar Vario Micro Cube instrument. 
N2 adsorption–desorption isotherms were recorded on a Quadrachrome QuadraSorb SI automated 
sorption analyzer. The samples were degassed at 60◦C for 5 h. Specific surface areas were calculated 
from the adsorption data in the low pressure range using the BET model and pore size was determined 
using the BJH method. TEM micrographs and EDX mappings were performed on a JEM 2100 F 
instrument (JEOL, Japan), operating at 200 kV. Dispersions of the particles in ethanol were applied 
onto carbon-coated copper grids (Plano, Formvar/coal-film on a 200mesh net). 
Particle preparation: CTAB (3.94 g) was dissolved in MeOH (360 g for A, 320 g for B and 280 g 
for C), and water (440 g for A, 480 g for B and 520 g for C) and 2.28 ml 1M NaOH were added under 
stirring at 400 rpm. After 10 min, TEOS (1.3 ml) was added dropwise, and stirring was continued for 
at least 8 h. After addition of NH4NO3 (30 g) the particles were isolated by centrifugation (10 min, 
10000 rpm) and washed with EtOH (50 ml). The particles were re-suspended into acidic EtOH (250 ml 
containing 1 g conc. HCl) by ultrasound treatment for 1 h, and then centrifuged. This process was 
repeated three times. After a final wash with pure EtOH the particles were dried at 160oC and a vacuum 
of 12 mm overnight. 
Cytotoxicity studies: HeLa cells were obtained from DSMZ (Deutsche Sammlung von 
Mikroorganismen und Zellkulturen) and cultured as attached monolayers in Dulbecco’s Modified 
Eagle’s Medium (DMEM, high glucose 4.5 g/L) with 10% fetal bovine serum, 1% MEM non-essential 
amino acids and 1% Penicillin/Streptomycin supplements. Cytotoxicity was determined by means of 
the luminescent cell viability assay CellTiter-Glo® [18], obtained from Promega, which measures  the 
ATP content of metabolically active cells (as a measure for the number of living cells), based on a 
luciferase reaction. Cultured cell monolayers were converted into single cell suspension by treatment 
with trypsin-EDTA solution, and then seeded into 96-well tissue culture plates at a density of 1 x 105 
cells per 100 μl. Cells were allowed to settle under standard culture incubation conditions for 24 h and 
then treated with freshly prepared sonicated suspensions of the platinum-loaded particles, or solutions 
of the Pt compound, at Pt concentrations in the cell medium of 2.5 μM and 10 μM, respectively. After 
24 h incubation under standard culture conditions cells were lysed for 10 minutes with the CellTiter-
Glo® reagent solution and the luminescence signal was read using a multiwell plate luminometer. The 
quantity of live cells was expressed relative to untreated control cells (“untreated”). Cell viability data 
given are mean values over three experiments. 
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